ArticleJAMA oncology2026

Disitamab Vedotin Plus Tislelizumab in Transurethrally Unresectable, ERBB2-Positive, Non-Muscle-Invasive Bladder Cancer: A Nonrandomized Clinical Trial.

Yunkai Qie et al.PubMed ↗Publisher ↗

No numbers read from the abstract.